Gamma-butyrolactone (GBL) is a clear, colorless industrial solvent and chemical intermediate that functions as a prodrug of GHB (gamma-hydroxybutyrate) through rapid lactonase-mediated hydrolysis in the body. Upon ingestion, the lactone ring of GBL is opened by lactonase enzymes present in blood and liver tissue to yield GHB directly, producing effects pharmacologically identical to GHB — sedation, euphoria, anxiolysis, and dose-dependent amnesia — but with a significantly faster onset than either GHB or its other prodrug, 1,4-butanediol (1,4-BD). GBL is converted to GHB essentially instantaneously upon contact with physiological fluids, producing onset within 5–15 minutes by oral route.
GBL occupies a critical position in the harm reduction landscape of GABAergic depressants: it produces identically the same effects and risks as GHB while having a substantially faster and more predictable onset than 1,4-BD, but the speed of onset combined with the narrow therapeutic window of the GHB class creates an even more compressed window between a recreational dose and a potentially fatal one. The difference between a dose that produces pleasant effects and one that causes unconsciousness may be as small as 0.5 mL; this window narrows dramatically with any concurrent alcohol use and varies with gastric contents.
Community experience underscores GBL's severe dependence liability — likely even higher than 1,4-BD due to the more efficient conversion and faster onset — and the harrowing nature of GHB/GBL withdrawal, which can include psychosis, seizures, and profound autonomic instability refractory to benzodiazepine treatment. GBL has historically been used at LGBTQ+ party settings and chemsex contexts in Europe, where harm reduction outreach has developed specific evidence-based guidance for this population. The industrial solvent status of GBL complicates regulation, as it has numerous legitimate commercial applications.
Safety at a Glance
High Risk- Precise Volume Measurement is Non-Negotiable
- Verify Concentration from Each New Source
- Toxicity: Extremely Narrow Safety Window The most critical safety concern with GBL is the narrow dose-response window. Recreati...
- Dangerous with: 2-Fluorodeschloroketamine, Acetylfentanyl, Alcohol, Atropa belladonna (+48 more)
- Overdose risk: LD50 is above the active dosage, and there is no danger of acute toxicity. However, it can become...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 1 hrs – 2 hrsHow It Feels
GBL makes itself known with an urgency that reflects its rapid conversion to GHB in the body. Within five to fifteen minutes of swallowing the sharp, solvent-like liquid, a warm rush surges upward from the stomach, flooding the chest and head with a sudden, pronounced euphoria. The speed of onset is one of GBL's defining features -- the transition from baseline to full effect is compressed into a window so narrow that the come-up can feel like a wave breaking directly overhead rather than building on the horizon.
The initial rush carries with it a burst of sociability and disinhibition. The world seems warmer and more welcoming, other people more interesting and attractive, and conversation flows with an ease that can feel almost magical. There is a physical dimension to the euphoria: muscles relax, the body feels light and warm, and physical touch becomes intensely pleasurable. Music seems to gain an extra dimension, its emotional content amplified and projected directly into the body. The overall sensation has been compared to the warmth of alcohol combined with the empathy of MDMA, though this comparison captures only the broad strokes of a more complex picture.
At the peak, the euphoria plateaus at a level that can feel almost overwhelmingly positive. The body hums with well-being, and there is a deep contentment that makes the present moment feel like the only moment that matters. Vision may take on a slightly dreamy quality, with enhanced color perception and a gentle blurring at the periphery. There is a characteristic looseness to the body -- movements are fluid but slightly uncoordinated, and there is a fine line between the pleasurable relaxation of an optimal dose and the heavy sedation that comes with pushing beyond it. Conversation remains easy and rewarding, though speech may acquire a slight looseness that mirrors the physical relaxation.
The descent is notably steep. The euphoria begins to fade within an hour of its peak, replaced by a growing drowsiness and a deepening sedation. The body becomes progressively heavier, and the pull toward sleep becomes powerful and difficult to resist. Sleep arrives quickly and deeply, and waking brings a clarity that is surprisingly clean -- minimal hangover, minimal cognitive fog, just a gentle return to baseline that can feel remarkably refreshing.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(8)
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Tremors— Involuntary rhythmic shaking of the hands, limbs, or body, ranging from fine tremor to gross shaking...
Cognitive & Perceptual Effects
Cognitive(8)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
Pharmacology
Mechanism of Action — Prodrug Conversion
GBL's mechanism of action is identical to GHB's, as GBL is an extremely efficient prodrug of GHB. Upon oral ingestion, GBL is absorbed rapidly from the GI tract; lactonase enzymes in blood and tissues (primarily paraoxonase-1, PON1) rapidly hydrolyze the lactone ring to yield GHB. The conversion is essentially instantaneous and complete — unlike 1,4-BD's two-step enzymatic conversion, GBL-to-GHB conversion occurs in blood and does not require liver processing.
GHB Pharmacology
GHB acts through:
- GHB receptors — Low-affinity neuromodulatory sites distributed throughout the brain; mediate euphoric and pro-dopaminergic components
- GABA-B receptors — At recreational doses, high-affinity GABA-B agonism dominates, producing sedation, respiratory depression, amnesia, and the characteristic loss of consciousness at supratherapeutic doses
GABA-B activation in the mesolimbic system disinhibits dopamine neurons, contributing to euphoria and reinforcement of repeated use.
Pharmacokinetic Comparison: GBL vs GHB vs 1,4-BD
| Property | GHB | GBL | 1,4-BD |
|---|---|---|---|
| Onset | 15–30 min | 5–15 min | 15–60 min |
| Conversion | Direct | Instant (blood) | Hepatic, 2 steps |
| Bioavailability | High | Higher than GHB | Variable |
| Duration | 2–4 hr | 2–4 hr | 2–4 hr |
GBL's faster onset relative to GHB means less time between ingestion and effect — reducing the window in which a user can recognize that a dose is taking effect and avoid redosing.
GHB Half-Life
GHB has a short plasma half-life of approximately 20–30 minutes. The abrupt offset of GHB effects creates significant craving and compulsive redosing behavior in dependent individuals, often leading to dosing every 2–4 hours around the clock.
Detection Methods
Standard Drug Panel Inclusion
Gamma-butyrolactone (GBL) is NOT included on any standard drug screening panel. It is not detected on 5-panel, 10-panel, or most extended drug tests. GBL is a prodrug that is rapidly converted to gamma-hydroxybutyrate (GHB) by peripheral lactonases after absorption. Once metabolized, it is subject to the same detection challenges as GHB: the body produces GHB endogenously, and the substance is rapidly metabolized, creating an extremely narrow window for detection.
Urine Detection
The detection window for GBL (measured as its metabolite GHB) in urine is extremely short: approximately 6 to 12 hours after a single dose. GHB is metabolized to succinic acid and carbon dioxide via the Krebs cycle, with a half-life of only 20 to 60 minutes. Endogenous GHB levels in urine range from 0.1 to 4 mcg/mL, and a cutoff of 10 mcg/mL is typically used to distinguish exogenous use from baseline endogenous production. After 12 hours, urinary GHB concentrations in most individuals have returned to endogenous levels, making detection impossible.
Blood and Serum Detection
Blood detection of GBL (as GHB) is limited to approximately 4 to 8 hours after ingestion. The rapid metabolism and short half-life mean that blood samples must be collected within hours of suspected exposure. Endogenous blood GHB concentrations are typically below 1 mcg/mL, and concentrations above 5 mcg/mL indicate exogenous exposure. Postmortem GHB concentrations are unreliable due to postmortem endogenous production.
Hair Follicle Detection
Hair testing for GHB has been developed using LC-MS/MS methods, with detection windows of up to 30 days. However, the distinction between endogenous and exogenous GHB in hair remains analytically challenging. A GHB-to-GBL ratio in hair has been proposed as a method to distinguish chronic exogenous use from baseline levels, but this approach has not been widely validated.
Confirmatory Methods
GC-MS and LC-MS/MS are used for GHB confirmation. Samples require prompt collection and preservation, as GHB can both degrade and be produced endogenously in stored biological specimens. Sodium fluoride preservative is recommended for blood samples to inhibit postmortem GHB formation. The analysis measures GHB directly, as GBL is fully converted before reaching the systemic circulation.
Reagent Testing
No standard reagent testing protocol exists for GBL. The liquid nature of GBL makes it difficult to test with standard reagent kits. GBL has a characteristic sharp, chemical taste and a faint solvent-like odor that distinguish it from water, but these are not reliable identification methods. Analytical chemistry methods are required for definitive identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 2-Fluorodeschloroketamine | Dangerous | — |
| Acetylfentanyl | Dangerous | — |
| Alcohol | Dangerous | — |
| Atropa belladonna | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Baclofen | Dangerous | — |
| Benzodiazepines | Dangerous | — |
| Buprenorphine | Dangerous | — |
| Cake | Dangerous | Combined CNS depression; risk of respiratory failure |
| Codeine | Dangerous | — |
| Datura | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Deschloroetizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Desomorphine | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Dextromethorphan | Dangerous | — |
| Dextropropoxyphene | Dangerous | — |
| Diclazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Dihydrocodeine | Dangerous | — |
| Diphenhydramine | Dangerous | Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure |
| Eszopiclone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Ethylmorphine | Dangerous | — |
| Etizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Fentanyl | Dangerous | — |
| Flubromazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flubromazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Flunitrazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Gaboxadol | Dangerous | Combined CNS depression; risk of respiratory failure |
| Harmala alkaloid | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Heroin | Dangerous | — |
| Hydrocodone | Dangerous | — |
| Hydromorphone | Dangerous | — |
| Ketamine | Dangerous | — |
| Kratom | Dangerous | — |
| Lorazepam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Mephenaqualone | Dangerous | Combined CNS depression; risk of respiratory failure |
| Methadone | Dangerous | — |
| Methoxetamine | Dangerous | — |
| Metizolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Midazolam | Dangerous | Combined CNS depression; risk of respiratory failure |
| Morphine | Dangerous | — |
| Naloxone | Dangerous | Severe respiratory depression risk; leading cause of polydrug overdose |
| Nicotine | Dangerous | Combined CNS depression; risk of respiratory failure |
| Nifoxipam | Dangerous | Combined CNS depression; risk of respiratory failure |
| O-Desmethyltramadol | Dangerous | — |
| Opioids | Dangerous | — |
| Oxycodone | Dangerous | — |
| Oxymorphone | Dangerous | — |
| PCP | Dangerous | — |
| Peganum harmala | Dangerous | Unpredictable potentiation of CNS depression; risk of respiratory failure |
| Pentobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| Pethidine | Dangerous | — |
| Phenobarbital | Dangerous | Combined CNS depression; risk of respiratory failure |
| SAMe | Dangerous | Combined CNS depression; risk of respiratory failure |
| 3-Cl-PCP | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-FMA | Caution | Masks the effects of each drug; risk of overdosing when one wears off before the other |
| 3-HO-PCE | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-HO-PCP | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-MeO-PCE | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-FA | Uncertain | — |
| 2-FMA | Uncertain | — |
| 3-FA | Uncertain | — |
| 3-FEA | Uncertain | — |
| 4-FA | Uncertain | — |
History
Industrial Chemical Origins
Gamma-butyrolactone is a major commercial chemical produced primarily from 1,4-butanediol through catalytic dehydrogenation. Global production is measured in hundreds of thousands of tons annually, used as a solvent, as a precursor to N-methylpyrrolidone (NMP), and as an intermediate in pharmaceutical and agrochemical synthesis. Its industrial prevalence complicates regulatory responses — scheduling GBL as a controlled substance would affect legitimate commerce far more broadly than scheduling most drugs.
Recognition as GHB Prodrug
GBL's activity as a GHB prodrug was recognized in the 1990s, particularly after GHB itself was scheduled in the United States. When GHB was placed on Schedule I in 2000, GBL became the primary accessible precursor and was marketed openly as a cleaning product and "supplement" with obvious recreational application. The FDA issued warnings about GBL-containing products in 1999.
Regulatory History
The US DEA placed GBL on its List I Chemicals, controlling it as a GHB precursor rather than as a scheduled substance. Sale of GBL intended for human consumption violates the Federal Analogue Act. The UK scheduled GBL as a Class C controlled substance in 2009. Regulatory responses in other jurisdictions vary widely, and GBL remains legally available in many countries as an industrial chemical.
Chemsex Context
From the late 2000s onward, GBL became commonly used in European LGBTQ+ party and chemsex contexts, often in combination with methamphetamine or mephedrone. Harm reduction organizations in the UK (including the Chemsex Clinic at 56 Dean Street, London) developed specific GBL harm reduction and dependency treatment protocols in response to significant community demand.
Harm Reduction
Precise Volume Measurement is Non-Negotiable
GBL doses must be measured in fractions of a milliliter. A standard kitchen measuring spoon is inadequate — a 1/4 teaspoon holds approximately 1.25 mL, and is not sufficiently accurate. Use a graduated dropper, syringe, or precision liquid measure. Prepare a diluted solution in known proportions if absolute volumes are too small to measure reliably.
Verify Concentration from Each New Source
GBL concentration may vary between suppliers. Never assume that a new batch has the same potency as previous batches. Start conservatively and titrate up from a reduced dose.
Wait a Full 30–45 Minutes Before Considering Redosing
Despite rapid onset, peak effects may continue building for 20–30 minutes. Redosing at 10–15 minutes because "I don't feel it yet" is a documented pattern preceding many overdoses.
Do Not Use Alcohol on the Same Occasion
This rule is absolute. No amount of alcohol is safe with GBL. Consume no alcohol for at least several hours before and after GBL use.
Use With a Sober Companion
Given the abrupt loss of consciousness that characterizes GBL overdose, a sober observer who can place someone in the recovery position and call emergency services is potentially life-saving. The recovery position (on side, not on back) prevents aspiration of vomit in unconscious individuals.
Recognize Dependence Early
If you find yourself dosing more frequently than once or twice per week, or if you are timing doses to avoid feeling unwell, this is a strong signal of developing physical dependence. Seeking medical advice before dependence becomes severe is critical — managing GBL/GHB withdrawal is significantly more dangerous and difficult than managing dependence earlier.
Do Not Drive
GBL produces dose-dependent impairment and its abrupt onset means it may begin affecting cognition and motor function after a user has started driving. Do not drive after use.
Toxicity & Safety
Extremely Narrow Safety Window
The most critical safety concern with GBL is the narrow dose-response window. Recreational doses are typically 0.5–2 mL of commercially available GBL solutions, but concentrations vary between sources. The difference between a recreational dose and one causing unconsciousness is often described as 0.5–1 mL. This margin is among the narrowest of any commonly used recreational substance.
Rapid Onset and Redosing Risk
GBL's fast onset (5–15 minutes) is faster than subjective recognition of peak effect — a user may not appreciate how impaired they are until they are deeply intoxicated. This contributes to accidental overdose from impatient redosing before the first dose's full effect is perceived.
Alcohol Synergy — Absolutely Lethal Combination
The combination of GBL/GHB with alcohol is the leading cause of GHB-class fatalities. Alcohol independently produces CNS and respiratory depression; combined with GHB-mediated GABA-B agonism at brainstem respiratory centers, the synergistic effect can produce fatal apnea at doses that would be individually survivable. This combination should be treated as absolutely contraindicated.
Severe Dependence and Withdrawal
GBL/GHB dependence is among the most severe known:
- Physical dependence can develop within weeks of daily use
- Around-the-clock dosing every 2–4 hours is reported by severely dependent users to prevent withdrawal
- Withdrawal syndrome: severe anxiety, tremor, autonomic instability, tachycardia, diaphoresis, and — critically — hallucinations, delusions, and psychosis that may not respond to benzodiazepines
- Grand mal seizures
- Potentially fatal without medical management
- Medical management typically requires phenobarbital or high-dose benzodiazepines with careful titration; IV GHB administration under medical supervision has also been used in some harm reduction settings
Industrial Contamination Risk
GBL is a commercial industrial solvent; product quality varies enormously between suppliers. Contaminants present in industrial-grade GBL may be present at varying concentrations.
Addiction Potential
highly physically and moderately to highly psychologically addictive
Overdose Information
LD50 is above the active dosage, and there is no danger of acute toxicity. However, it can become dangerous when used as a recreational drug, abused, or in combination with other drugs. There have been many negative reports from recreational users who have overdosed, combined GBL with alcohol or other drugs, or accidentally dosed themselves unexpectedly or way above the common dosage range.
To avoid a possible overdose of GBL, it is important to start with a low dose and work your way up slowly by increasing the dosage in small increments. One should best use a glass bottle with an integraded 1ml pipette to exactly measure their dosages.
Accidental ingestions of GBL have also occurred due to inadequate storage methods. If GBL is put into a clear liquid, glass, or bottle, it can be easily mistaken for water. It is recommended to clearly label your GBL in writing and dye the liquid with blue food coloring so it no longer resembles a drinkable beverage. It is also recommended to store your GBL in a container that no one would drink out of.
It is strongly recommended that one use harm reduction practices when using this drug.
- Neurotoxicity
GBL itself may also produce neurotoxic effects, in addition to the effects of GHB, to which it is converted to by the body.
, and alcohol.]]highly physically and moderately to highly psychologically addictive. The frequent use of GBL can cause withdrawal symptoms similar to those caused by other depressants such as alcohol and benzodiazepines if abruptly discontinued, reportedly with a much faster onset and more severe symptoms when used frequently. Withdrawal effects from GBL build faster than with GHB. These symptoms seem to depend on the dosage and the length of time the drug was used for. Light to moderate users often experience anxiety, insomnia, sleep-related problems, and tremors whereas heavy use can cause severe withdrawal symptoms like delirium, psy
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression risk; leading cause of polydrug overdose
Combined CNS depression; risk of respiratory failure
Compounding CNS depression with anticholinergic effects; risk of cardiac events and respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Severe respiratory depression risk; leading cause of polydrug overdose
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Unpredictable potentiation of CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Combined CNS depression; risk of respiratory failure
Tolerance
| Full | within several days of continuous use |
| Half | Unknown |
| Zero | 7 - 14 days |
Cross-tolerances
Legal Status
Australia:** GBL is a border controlled substance and is illegal to import into Australia without a permit. The importation of a commercial quantity of a border controlled drug (over 1 kg of GBL) is punishable by up to life imprisonment and/or an $825,000 fine.
Austria:** Since January 1, 2012, GBL is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Canada:** GBL is a Controlled Substance under Schedule VI of the "Controlled Drugs and Substances Act" in Canada. Schedule VI of the "Controlled Drugs and Substances Act" requires vendors to collect information regarding purchases of GBL. The Act also prohibits the import and export of GBL into or out of Canada classifying it as either an indictable offence punishable with up to 10 years in prison or an offence punishable on summary conviction liable to imprisonment for up to eighteen months. It is not illegal for an individual to possess GBL in Canada.
Germany:** GBL is not listed in the narcotics law, but its distribution is controlled. Possession is not illegal, but may be punished according to the Medicines Act, when intended to be sold for human consumption or synthesis of GHB. In recent years, an increase of GBL consumption has been observed due to the prohibition of GHB.
Hong Kong:** GBL is a dangerous drug controlled under Schedule 1 of the Dangerous Drugs Ordinance, Cap.134 (with exemption clause at Paragraph 16D). Any person who is found to have in his possession of it not in accordance with this Ordinance can be liable, on conviction upon indictment, a fine of HK$1,000,000 and to imprisonment for 7 years.
Israel:** GBL was classified as a proscribed substance from 2007.
Netherlands: GBL can be freely bought as a cleaning agent. Retailers do not need a licence to sell the substance.
Poland:** GBL is classified as a drug and handling it requires a pharmaceutical license.
Sweden:** GBL is not classified as a drug but as a health-endangering substance. Although recently passed legislation to enter into force on 1 April 2011 will make it possible to handle narcotics for industrial purposes will enable GBL and 1,4-Butanediol to be classified as controlled substances.
Switzerland:** GBL is considered an ester analog of GHB, which would make it illegal according to Buchstabe B. Industrial use however is permitted.
Turkey:** GBL is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom:** Because of their legitimate uses, regulation 4B of the 2001 regulations makes it lawful to import, export, produce, supply, offer to supply or possess GBL and 1,4-BD. Except where a person does so knowing or believing that they will be used for the purpose of human ingestion.
United States:** GBL is regulated as a List 1 controlled chemical. As a GHB analog, it is treated as a controlled substance under Schedule I of the "Controlled Substances Act" if intended for human consumption.
Responsible use
Depressants
GHB
1,4-Butanediol
GBL (Wikipedia)
GBL (Isomer Design)
GBL (Drugs-Forum)
Experience Reports (2)
Tips (5)
Physical dependence on GBL can develop faster than expected with regular use. Depressant withdrawal can cause seizures, delirium, and death. Never abruptly stop after prolonged daily use; taper gradually under medical guidance.
Inform a trusted person when using GBL, especially if alone. Depressant overdoses can cause you to lose consciousness before you can call for help. Someone should be able to check on you.
If you are considering quitting GBL after regular use, consult a medical professional. Depressant withdrawal can be medically dangerous and a supervised taper is the safest approach. Do not try to white-knuckle it.
With GBL, the dose-response curve is steep near the top end. A dose that feels mildly intoxicating might be only 50% more than a dose that causes unconsciousness. Always err on the side of caution.
Start with a low dose of GBL and wait for full onset before considering more. Depressants have a narrow margin between recreational and dangerous doses. Redosing while already impaired leads to accidental overdose.
See Also
References (3)
- PubChem: GBL
PubChem compound page for GBL (CID: 7302)
pubchem - GBL - TripSit Factsheet
TripSit factsheet for GBL
tripsit - GBL - Wikipedia
Wikipedia article on GBL
wikipedia